论文部分内容阅读
虽然阿糖腺苷和干扰素已成功地用于泡疹病毒感染病人的治疗,但对巨细胞病毒(CMV)感染尚无满意的疗效。本文旨在观察干扰素和阿糖腺苷联合应用对骨髓移植后CMV肺炎的治疗作用。所有骨髓移植后病人(7例)均经肺活检证实具有CMV细胞内包涵体性肺炎。用人白细胞干扰素12小时肌注一次,阿糖腺苷在12小时内静脉持续滴入。如果未观察到骨髓毒性反应(即中性白细胞计数不低于治疗前5天平均数的60%),则每5天增加一次治疗剂量;如果发生毒性反应,则中止治疗直到中性白细胞计数恢复。
Although vidarabine and interferon have been successfully used in the treatment of patients with herpes virus infection, there is no satisfactory response to cytomegalovirus (CMV) infection. This article aims to observe the combination of interferon and vidarabine treatment of CMV pneumonia after bone marrow transplantation. All patients after bone marrow transplantation (7 cases) were confirmed by lung biopsy with CMV intracellular inclusion pneumonia. Human leukocyte interferon 12 hours intramuscular injection, intravenous adenosine intravenous infusion within 12 hours. The therapeutic dose is increased every 5 days if no bone marrow toxicity reaction is observed (ie, the neutrophil count is not less than 60% of the mean 5 days prior to treatment); if there is a toxic reaction, the treatment is discontinued until the neutrophil count is restored .